Research Support

Research at the IQVIA Institute for Human Data Science

The IQVIA Institute conducts empirically rigorous, policy-relevant studies to improve the quality and cost-effectiveness of healthcare. The Institute includes members from a variety of disciplines including pharmacy, medicine, law, economics, business, and public policy.

Recently completed projects range from an examination of national trends in prescription drug expenditure, global oncology and medicines use.

IQVIA Bibliography

Provides a summary of research published from January 2010 through December 2017 that was undertaken by U.S.-based researchers and utilized IQVIA data assets.

Shaping the Future of Healthcare

Through collaboration with the IQVIA Institute, researchers and students have access to a broad range of proprietary databases and tools to support independent research, discovery work and requirement development for future funded studies.

IQVIA Real-World Data Adjudicated Claims (PharMetrics Plus)
• Fully adjudicated health plan claims information
• 130 million non-identified lives in the U.S.
• Single integrated database, updated quarterly
• Available at the three-digit zip code level
• History back to 2007

IQVIA Prescription Drug Data
• Over 90% coverage for dispensed prescriptions
• National views and sub-national views to state, county, zip code or prescriber granularity
• Retail, mail and long-term care channels
• Age, gender, co-pay, method of payment and payer details

IQVIA OneKey Reference Assets
• Organization and professional reference data
• Includes NPI, AMA, SLN, DEA, and AOA
• Over 600,000 organizations and >8.9Mil professionals (~2.1mil prescriber eligible)
• Includes physicians, nurse practioners and physician assistants
• Includes ACOs, IDNs and affiliations

Research Priorities

The IQVIA Institute welcomes proposals examining most aspects of healthcare, projects that are directly relevant to ongoing healthcare reform are of greatest interest. High-priority areas include

Comparative Effectiveness Research
• Evaluations of which interventions work best, for whom, and under what circumstances
• Analyses of how comparative effectiveness research is reflected in clinical practice

Drug Utilization Trends and Expenditures

• Analysis of national trends in prescription drug utilization and office-based care
• Examination of adoption of new therapies among patient and physician subpopulations
• Evaluation of prescription use and expenditures and factors that influence these trends

Real-World Practice

• Analysis of association between patient, physician, and health system characteristics and practice patterns
• Establishment of best practices and quality metrics for specific conditions or populations, including for preventive care and screening
• Utilization trends and costs in specific medical areas, such as oncology, cardiovascular disease or rare diseases where orphan drugs or specialty drugs are used
• Investigations of socioeconomic, racial, or ethnic disparities in processes or outcomes of care

Geographic Variations in Care
• Examination of geographic variations in treatments, costs and outcomes
• Ecologic studies examining how geographic variation in prescription use (e.g., antibiotics) is associated with specific outcomes (e.g., antimicrobial resistance)
• Studies using geographic variation in use to infer information regarding disease or treatment prevalence

The USC is a categorization system that resolves the need for therapeutic classification of pharmaceutical products.